OPEN ACCESS Freely available online

Endocrinology & Metabolic Syndrome

Opinion Article

# Genetic Insights into Hypogonadotropic Hypogonadism

**Yanzhi Du***

*Department of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, USA*

## DESCRIPTION

Hypogonadotropic hypogonadism is a rare endocrine disorder characterized by inadequate gonadal function due to insufficient secretion of gonadotropin-releasing hormone. GnRH is a key hormone that stimulates the production of follicle-stimulating hormone and luteinizing hormone from the anterior pituitary gland. These hormones are essential for the development of secondary sexual characteristics and the maintenance of reproductive health. HH can be caused by a variety of genetic mutations affecting the hypothalamic-pituitary-gonadal axis. In this article, we will explore the genetics of hypogonadotropic hypogonadism, highlighting the key genes and mechanisms involved in this condition.

### Types of hypogonadotropic hypogonadism

Hypogonadotropic hypogonadism can be categorized into two main types based on its onset and genetic causes:

**Isolated hypogonadotropic hypogonadism:** In IHH, the dysfunction is limited to the reproductive system, with normal development of other endocrine glands. This form of HH often presents with delayed puberty or infertility.

**Syndromic hypogonadotropic hypogonadism:** Syndromic HH is associated with additional features and systemic abnormalities. These features can include anosmia (lack of sense of smell), cleft lip/palate, or skeletal anomalies. Syndromic forms of HH are often associated with genetic mutations that affect multiple systems.

### Genes implicated in hypogonadotropic hypogonadism

Numerous genes have been implicated in the pathogenesis of hypogonadotropic hypogonadism. These genes can be broadly categorized based on their roles in the hypothalamic-pituitary-gonadal axis:

**GnRH and GnRH receptor mutations:** Mutations in the genes encoding GnRH or its receptor (GNRHR) can disrupt the normal pulsatile release of GnRH, leading to HH. These mutations often result in normosmic IHH, a form of HH without anosmia.

**Kallmann syndrome-related genes:** Kallmann syndrome is a syndromic form of HH characterized by anosmia or hyposmia (reduced sense of smell) in addition to reproductive dysfunction. Mutations in several genes have been associated with Kallmann syndrome, including *KAL1* (encoding anosmin-1), *FGFR1* (fibroblast growth factor receptor 1), *PROK2* (prokineticin 2), and *PROKR2* (prokineticin receptor 2). These genes play essential roles in neuronal migration and development, and their mutations disrupt GnRH neuron migration to the hypothalamus.

**Pituitary transcription factor mutations:** Mutations in genes encoding pituitary transcription factors, such as *KISS1R* (kisspeptin receptor), *TACR3* (tachykinin receptor 3), and *GNRHR* (gonadotropin-releasing hormone receptor), can lead to HH by affecting the development or function of the pituitary gland.

**Other syndromic genes:** Syndromic HH can be caused by mutations in genes that are not directly related to the reproductive axis but impact the development of various systems.

For example, mutations in *CHD7* (chromodomain helicase DNA-binding protein 7) cause CHARGE syndrome, which includes HH as one of its features.

**Genes involved in gonadotropin synthesis and action:** Mutations in genes related to the synthesis or action of FSH and LH can result in HH. For instance, mutations in the *FSHB* gene (encoding FSH beta-subunit) or *FSHR* gene (encoding FSH receptor) can disrupt FSH function.

**Genes involved in Steroidogenesis:** Steroid hormones are essential for reproductive function. Mutations in genes involved in steroidogenesis, such as LH receptor and steroidogenic acute regulatory protein, can lead to HH by affecting gonadal hormone production.

### Genetic testing and diagnosis

The diagnosis of hypogonadotropic hypogonadism often involves

**Correspondence to** Yanzhi Du, Department of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, USA, E-mail: yanzhid@gmail.com

**Received:** 14-Aug-2023, Manuscript No. EMS-23-27435; **Editor assigned:** 16-Aug-2023, Pre QC No. EMS-23-27435 (PQ); **Reviewed:** 01-Sep-2023, QC No. EMS-23-27435; **Revised:** 08-Sep-2023, Manuscript No. EMS-23-27435 (R); **Published:** 15-Sep-2023, DOI: 10.35248/2161-1017.23.12.386.

**Citation:** Du Y (2023) Genetic Insights into Hypogonadotropic Hypogonadism. Endocrinol Metab Syndr.12: 386.

a combination of clinical evaluation and genetic testing. Clinical features, such as delayed puberty or infertility, can provide initial clues. Measurement of serum gonadotropin and sex hormone (estrogen or testosterone) levels can help confirm the diagnosis. Low levels of gonadotropins and sex hormones in the presence of normal pituitary function are indicative of HH.

Genetic testing, including next-generation sequencing and whole exome sequencing, has become a valuable tool for identifying the genetic mutations underlying HH. Identifying the genetic cause of HH can have important implications for treatment and family planning, as some forms of HH may be hereditary.

## Treatment of hypogonadotropic hypogonadism

The treatment of hypogonadotropic hypogonadism typically involves hormone replacement therapy to restore normal levels of sex hormones. In males, this may include testosterone replacement therapy, while in females, hormone replacement therapy with estrogen and progesterone may be prescribed. Treatment can help induce puberty, promote secondary sexual characteristics, and improve fertility.

In some cases, treatment may also involve addressing underlying genetic causes, such as correcting anosmia in Kallmann syndrome or managing associated symptoms in syndromic forms of HH. Hypogonadotropic hypogonadism is a complex endocrine disorder with diverse genetic underpinnings. Understanding the genetic basis of HH is vital for diagnosis, treatment, and genetic counseling. Advances in genetic testing and research continue to expand our knowledge of the genetic mutations that contribute to HH, and it is more personalized and effective therapeutic approaches for individuals affected by this condition.